Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study

NCT06862869 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06862869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06862869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Recruiting
Start date
April 30, 2025
Completion date
February 28, 2030
Enrollment
800 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung